Preparation and evaluation of phytantriol liquid crystal as a liquid embolic agent

References

• Ahnfelt E, Sjögren E, Hansson P, Lennernäs H. 2016. In vitro release mechanisms of doxorubicin from a clinical bead drug-delivery system. J Pharm Sci. 105(11):3387–3398.
   PubMed Web of Science ®Google Scholar
• Akbar S, Anwar A, Ayish A, Elliott JM, Squires AM. 2017. Phytantriol based smart nano-carriers for drug delivery applications. Eur J Pharm Sci. 101:31–42.
   PubMed Web of Science ®Google Scholar
• Cao JJ, Huang J, Gui SY, Li ZG, Li Q, Zhang Y, Wang XQ, Chu XQ. 2018. [Rheological properties of sinomenine in situ liquid crystal as liquid embolic agent]. Zhongguo Zhong Yao Za Zhi. 43(12):2522–2530. Chinese.
   PubMedGoogle Scholar
• Chabrot P, Fatimi A, Fraine PD, Ouchchane L, Dauplat MM, Rivard A, Lerouge S, Soulez G. 2012. Embolization and endothelial ablation with chitosan and sodium sotradecol sulfate: preliminary results in an animal model. J Endovasc Ther. 19(3):439–449.
   PubMed Web of Science ®Google Scholar
• Chen YL, Gui SY, Liang X, Wang SM, Jiang XJ. 2016. [Preparation and evaluation of intra-articular injectable sinomenine hydrochloride-loaded in situ liquid crystals]. Acta Pharm Sin. 51(1):132–139. Chinese.
   Google Scholar
• Cheng M, Gao X, Wang Y, Chen H, He B, Xu H, Li Y, Han J, Zhang Z. 2013. Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo. Mar Drugs. 11(9):3517–3536.
   PubMed Web of Science ®Google Scholar
• Dima C, Pătraşcu L, Cantaragiu A, Alexe P, Dima Ş. 2016. The kinetics of the swelling process and the release mechanisms of Coriandrum sativum L. essential oil from chitosan/alginate/inulin microcapsules. Food Chem. 195:39–48.
   PubMed Web of Science ®Google Scholar
• Forner A, Gilabert M, Bruix J, Raoul JL. 2014. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 11(9):525–535.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. 2012. Hepatocellular carcinoma. Lancet. 379(9822):1245–1255.
   PubMed Web of Science ®Google Scholar
• Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. 2017. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. JHC. 4:93–103.
   Google Scholar
• Han K, Pan X, Chen M, Wang R, Xu Y, Feng M, Li G, Huang M, Wu C. 2010. Phytantriol-based inverted type bicontinuous cubic phase for vascular embolization and drug sustained release. Eur J Pharm Sci. 41(5):692–699.
   PubMed Web of Science ®Google Scholar
• Kazekawa K, Iwata H, Shimozuru T, Sampei K, Sakaki N, Morikawa N, Matsuda S, Ikada Y. 1997. Nontoxic embolic liquids for treatment of arteriovenous malformations. J Biomed Mater Res. 38(2):79–86.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Petruzzi P, Crocetti L. 2013. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 30(1):3–11.
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, et al. 2019. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread. J Vasc Interv Radiol. 30(3):349–357.e342.
   PubMed Web of Science ®Google Scholar
• Ming ZJ, Hu Y, Qiu YH, Cao L, Zhang XG. 2010. Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine. 17(8-9):575–580.
   PubMed Web of Science ®Google Scholar
• Qian K, Ma Y, Wan J, Geng S, Li H, Fu Q, Peng X, Kan X, Zhou G, Liu W, et al. 2015. The studies about doxorubicin-loaded p(N-isopropyl-acrylamide-co-butyl methylacrylate) temperature-sensitive nanogel dispersions on the application in TACE therapies for rabbit VX2 liver tumor. J Control Release. 212:41–49.
   PubMed Web of Science ®Google Scholar
• Qin L, Mei L, Shan Z, Huang Y, Pan X, Li G, Gu Y, Wu C. 2016. Phytantriol based liquid crystal provide sustained release of anticancer drug as a novel embolic agent. Drug Dev Ind Pharm. 42(2):307–316.
   PubMed Web of Science ®Google Scholar
• Qin LZ, Zhang X, Wu LN, Zhang J, Pan X, Li G, Wu CB. 2014. [Preparation and in vitro embolic efficiency evaluation of hydroxycamptothecine-loaded liquid embolic agent]. Acta Pharm Sin. 49(7):1069–1075. Chinese.
   Google Scholar
• Schwarz A, Zhang H, Metcalfe A, Salazkin I, Raymond J. 2004. Transcatheter embolization using degradable crosslinked hydrogels. Biomaterials. 25(21):5209–5215.
   PubMed Web of Science ®Google Scholar
• Sho T, Nakanishi M, Morikawa K, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Nakai M, Suda G, et al. 2017. A phase I study of combination therapy with sorafenib and 5-fluorouracil in patients with advanced hepatocellular carcinoma. Drugs R D. 17(3):381–388.
   PubMed Web of Science ®Google Scholar
• Simionato LD, Petrone L, Baldut M, Bonafede SL, Segall AI. 2018. Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina. Saudi Pharm J. 26(4):578–584.
   PubMed Web of Science ®Google Scholar
• Tam KY, Leung K-F, Wang Y-X. 2011. Chemoembolization agents for cancer treatment. Eur J Pharm Sci. 44(1–2):1–10.
   PubMed Web of Science ®Google Scholar
• Wang C, Liu J, Pan W, Wang X, Gao Q, Hou S. 2008. Pingyangmycin loaded bovine serum albumin microspheres for chemoembolization therapy—in vitro and in vivo studies. Int J Pharm. 351(1–2):219–226.
   PubMedGoogle Scholar
• Zhang X, Zhong JL, Liu W, Gao Z, Xue X, Yue P, Wang L, Zhao C, Xu W, Qu X. 2010. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU. Cancer Chemother Pharmacol. 66(1):11–19.
   PubMed Web of Science ®Google Scholar
• Zhou X, Kong M, Cheng XJ, Feng C, Li J, Li JJ, Chen XG. 2014. In vitro and in vivo evaluation of chitosan microspheres with different deacetylation degree as potential embolic agent. Carbohydr Polym. 113:304–313.
   PubMed Web of Science ®Google Scholar